<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">IJCM</journal-id><journal-title-group><journal-title>International Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2158-284X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ijcm.2015.66049</article-id><article-id pub-id-type="publisher-id">IJCM-56947</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Effect of Carotid Artery Stenting and Extracranial-Intracranial By-Pass on Cognitive Function: Preliminary Results
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>i</surname><given-names>Liu</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yuying</surname><given-names>Zhou</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Department of Radiology, Tianjin Huan Hu Hospital, Tianjin, China</addr-line></aff><aff id="aff2"><addr-line>Department of Neurology, Tianjin Huan Hu Hospital, Tianjin, China</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>zhouyuyinghh@163.com(YZ)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>06</month><year>2015</year></pub-date><volume>06</volume><issue>06</issue><fpage>377</fpage><lpage>383</lpage><history><date date-type="received"><day>1</day>	<month>May</month>	<year>2015</year></date><date date-type="rev-recd"><day>accepted</day>	<month>1</month>	<year>June</year>	</date><date date-type="accepted"><day>5</day>	<month>June</month>	<year>2015</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   Background: To compare the neuropsychological consequences after carotid artery stenting (CAS) and extracranial-intracranial by-pass (EC-IC by-pass). Methods: A total of 43 patients referred to CAS, 32 patients referred to EC-IC by-pass and 43 control subjects were enrolled in the study. Neuropsychologic testing was performed before and three months after procedure. A paired Student t test was use
   d to compare neuropsychologic test scores at baseline and three months after procedure in each group. Cognitive changes in a three-month follow-up were not normally distributed and compared among/between groups with Kruskal-Wallis test. Results: Three months after the treatment both the CAS and EC-IC by-pass groups showed improved cognitive performance compared to baseline, whereas the same improvement wasn’t seen in the control group. The scores from Activities of Daily Living also improved in all three groups in a three-month follow-up, and EC-IC group presented a more distinct increase in daily life abilities comparing to the other two groups. Conclusions: CAS and EC-IC by-pass in patients with a carotid or intracranial stenosis may result in cognitive improvement three months after surgery. 
  
 
</p></abstract><kwd-group><kwd>Carotid Artery Stenting</kwd><kwd> Extracranial-Intracranial By-Pass</kwd><kwd> Cognition</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Atherosclerosis of the extracranial and intracranial artery is an important mechanism underlying cerebrovascular disease, and has been demonstrated to be associated with stroke [<xref ref-type="bibr" rid="scirp.56947-ref1">1</xref>] , cognitive impairment [<xref ref-type="bibr" rid="scirp.56947-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.56947-ref3">3</xref>] and dementia [<xref ref-type="bibr" rid="scirp.56947-ref4">4</xref>] . It can reduce cerebral perfusion [<xref ref-type="bibr" rid="scirp.56947-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.56947-ref6">6</xref>] , which further causes oxidative stress, mitochondrial dysfunction, and neuroinflammation [<xref ref-type="bibr" rid="scirp.56947-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.56947-ref8">8</xref>] , and eventually leads to neuropathological changes and cognitive performance decline. To reduce the risk of stroke, carotid artery stenting (CAS) is performed and has shown to be effective in preventing from stroke in patients with severe carotid artery stenosis. For patients with intracranial stenosis, especially caused by intracranial atherosclerotic disease (ICAD), medical intervention is required to reduce the risk of ischemic stroke due to thromboembolic events, but it does not reduce the risk of ICAD progression, hypoperfusion and poor collateral circulation. Therefore extracranial-intracranial (EC-IC) bypass was developed to reduce the risk of ischemic stroke in patients with impaired cerebral hemodynamics due to occlusive cerebrovascular disease. Several studies have shown that restoration of blood flow after CAS or EC-IC by-pass may improve cognitive function [<xref ref-type="bibr" rid="scirp.56947-ref9">9</xref>] - [<xref ref-type="bibr" rid="scirp.56947-ref12">12</xref>] . Conversely some authors had concerns that revascularization may have a negative impact on cognition caused by procedural emboli, general anesthesia, or temporary flow interruption [<xref ref-type="bibr" rid="scirp.56947-ref13">13</xref>] . Further studies are needed to confirm the role of revascularization on cognition. The goal of this retrospective study was to evaluate cognitive performance in patients following CAS and EC-IC by-pass.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Study Patients</title><p>Consecutive patients who were referred to neuroendovascular unit for carotid artery stent placement or EC-IC by-pass from January 2010 to October 2011 participated in the study. The institutional review board approved the study. The degree of carotid and intracranial stenosis was initially evaluated by CT angiogram (CTA), and conventional cerebral angiography was followed in anticipation of CAS and EC-IC by-pass. Brain MR perfusion-weighted imaging was performed in all subjects. Inclusion criteria included recent (within 30 days of the date of procedure) CTA of the head and neck, evidence of an carotid stenosis of more than 70% confirmed with conventional angiography or severe intracranial major artery stenosis with distinct low perfusion of the relevant regions, age older than 45 years, and selected by the vascular disease specialist as a suitable candidate for stent placement or EC-IC by-pass. CAS was performed if the patients had severe symptomatic carotid stenosis ≥70% without severe diffused intracranial artery stenosis. The indications for EC-IC bypass surgery were haemodynamic compromise due to atherosclerotic occlusive cerebrovascular disease which was demonstrated by the MRI perfusion imaging. Controls were patients with carotid or/and intracranial severe stenosis who declined vascular surgery due to personal reasons or no surgery was possible due to medical reasons. Exclusion criteria included evidence of a previous large stroke or cerebral infarction, a history of previous subarachnoid or cerebral hemorrhage, intracranial arteritis and cerebral arteriopathy. All patients including controls received aspirin 100 mg and clopidogrel 75 mg daily after the procedure.</p></sec><sec id="s2_2"><title>2.2. Methods</title><p>We collected demographic information and the vascular risk factors of each patient. Neuropsychologic testing was conducted by a trained research assistant. Global cognitive function was assessed using the Mini-Mental State Examination (MMSE) and Montreal cognitive assessment (MoCA), self-care abilities were assessed with Activities of Daily Living (ADLs), and patient’s mood was assessed with the Hamilton Rating Scale for Depression (HMLD). Both MMSE and MoCA are screening tests for assessing the cognitive state of patients and are simple to use, sensitive, and valid. From the inclusion into clinical practice they have been proven as reliable and suitable for the initial assessment of mental status follow-up. The MMSE examines the temporal and spatial orientation, memory skills (immediate and delayed), attention, oral and written language, and constructional abilities in two dimensions. The MMSE has eleven tasks where each one scores a number of points, total score is 30 points, and the scale ranges from 0 to 30, so that there are levels of severe cognitive impairment (from 0 to 17 points); medium impairment (from 18 to 23 points); and without impairment (from 24 to 30 points). The MoCA investigates patient’s skills in 5 domains: visuospatial/executive, naming, memory, attention, abstraction, and orientation. The total score is the sum of all items, with a maximum score of 30 (best performance). The ADL is a carer rated instrument consisting of 20 daily-living ability items. For each item, four dimensions on initiation, organization and effectiveness to carry out a specific task would be measured to give an overall rating. HMLD assesses depression through 21 questions. The higher the score, the more severe the depression as follows: 0 - 7 no depression; 8 - 13 mild depression; 14 - 18 moderate depression; 19 - 22 severe depression; ≥23 very severe depression. All Assessments were performed before and 3 months after surgery.</p></sec><sec id="s2_3"><title>2.3. Statistical Analysis</title><p>All measurement data are presented as mean &#177; SD or median &#177; quartile as appropriate. Categorical data are given as counts. Chi-square tests were performed to compare categorical variables such as gender, history and risk factors in cross tables. One-way ANOVA were performed to compare measurement baseline characteristics. We used a paired Student t test to compare neuropsychologic test scores at baseline and at three months after procedure in each group. Cognitive assessment score changes in a three-month follow-up were not normally distributed and compared among/between groups with Kruskal-Wallis Test. Differences were deemed statistically significance if P &lt; 0.05. We performed all statistical analyses with SPSS version 13.0 (SPSS, Chicago, IL).</p></sec></sec><sec id="s3"><title>3. Results</title><p>We totally enrolled 118 patients into the study. Of the 118 patients, 43 were performed CAS, 32 were performed EC-IC by-pass, and 43 conformed to CAS/EC-IC criteria but declined any surgery. No periprocedural adverse clinical events were noted. Demographics, clinical symptoms and vascular risk factors except for age showed no significant differences among the CAS, EC-IC by-pass and control groups. There were younger patients in the EC-IC by-pass group. There were no significant differences in baseline MMSE, MoCA, ADLs and HMLD scores among the groups (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>The MMSE and MoCA scores did not significantly change from baseline in the control patients at three- month follow-up (P = 0.323 and 0.685). In CAS group, the total scores for the MMSE and MoCA increased significantly to 26.37 and 23.23 three months after stent placement comparing to the baseline average 25.16 and 21.37 (P &lt; 0.001). As to EC-IC by-pass group, the average MMSE and MoCA scores also increased significantly to 26.59 and 24.13 from 25.13 and 21.88 three months after EC-IC by-pass surgery (<xref ref-type="table" rid="table2">Table 2</xref>). The changes on the MMSE and MoCA scores from baseline differed significantly among the three groups (<xref ref-type="table" rid="table3">Table 3</xref>). Both CAS and EC-IC by-pass groups had improvement on cognitive performance compared to the control group (<xref ref-type="table" rid="table4">Table 4</xref>). Comparison of the change scores for the MMSE and MoCA showed no significant differences between the CEA and EC-IC by-pass groups (P = 0.264 and 0.289 respectively).</p><p>Both the ADLs and HMLD significantly improved from baseline in all three groups after three months (<xref ref-type="table" rid="table2">Table 2</xref>), and EC-IC group presented a greater recovery in daily life abilities comparing to the other two groups (<xref ref-type="table" rid="table3">Table 3</xref>, <xref ref-type="table" rid="table4">Table 4</xref>). There were no significant differences in the changes of HMLD scores among three groups (<xref ref-type="table" rid="table3">Table 3</xref>).</p></sec><sec id="s4"><title>4. Discussion</title><p>The principal aim of our investigation was to determine whether patients experienced improved cognition following CAS or EC-IC by-pass. In our study, patients before stent placement had, on average, total MMSE score of 25.51 and MoCA score of 22.01, with which MoCA was lower than the normal value. The scores for both MMSE and MoCA increased significantly after stent placement. The same cognitive improvement effect was also seen in EC-IC by-pass group, whereas there was no significant difference comparing to baseline after three months in the control group.</p><p>CAS is believed to prevent stroke as a less invasive alternative to carotid endarterectomy (CEA) in selected patients with symptomatic carotid stenosis [<xref ref-type="bibr" rid="scirp.56947-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.56947-ref15">15</xref>] , but its influence on cognitive performance in patients remains controversial [<xref ref-type="bibr" rid="scirp.56947-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.56947-ref17">17</xref>] . The results in our study agreed with the results from previous reports which have shown improvements in cognitive function in patients treated with carotid stent placement [<xref ref-type="bibr" rid="scirp.56947-ref18">18</xref>] -[<xref ref-type="bibr" rid="scirp.56947-ref22">22</xref>] . In addition, the average MoCA score of the patients from all three groups was below the normal value. To data, there has not been a significant study of the incidence of cognitive dysfunction in patients with carotid artery stenosis. It is speculative that majority of patients with severe carotid and/or intracranial major artery stenosis experience cognitive impairment to some degree. The possible mechanisms of a cognitive impairment include silent embolization and hypoperfusion in brain. Carotid stenting may lead to an increment and restoration in brain perfusion, and eventually improve patients’ cognitive function. The reports suggesting a potential cognitive deterioration from CAS were mostly in the earlier introduction of carotid stent before emboli-protection devices (EPDs) were developed [<xref ref-type="bibr" rid="scirp.56947-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.56947-ref24">24</xref>] . The post-CAS cognitive dysfunction was thought to be a consequence of microembolic ischemia or intraprocedural hypoperfusion. In all our CAS patients, a distal filter was deployed during the procedure, which reduced the risk of stent-related particle emboli and strokes.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Demographics, vascular risk factors and baseline cognitive function in the CAS, EC-IC by-pass and control groups</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >CAS (n = 43)</th><th align="center" valign="middle" >EC-IC (n = 32)</th><th align="center" valign="middle" >Control (n = 43)</th><th align="center" valign="middle" >F/χ<sup>2</sup></th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >Age</td><td align="center" valign="middle" >63.26 &#177; 8.353</td><td align="center" valign="middle" >56.44 &#177; 9.098</td><td align="center" valign="middle" >62.53 &#177; 8.192</td><td align="center" valign="middle" >6.803</td><td align="center" valign="middle" >0.002</td></tr><tr><td align="center" valign="middle" >Gender (female/male)</td><td align="center" valign="middle" >18/25</td><td align="center" valign="middle" >12/20</td><td align="center" valign="middle" >25/18</td><td align="center" valign="middle" >3.754</td><td align="center" valign="middle" >0.153</td></tr><tr><td align="center" valign="middle" >Education (yrs)</td><td align="center" valign="middle" >8.63 &#177; 3.684</td><td align="center" valign="middle" >9.69 &#177; 3.207</td><td align="center" valign="middle" >9.23 &#177; 3.265</td><td align="center" valign="middle" >0.914</td><td align="center" valign="middle" >0.404</td></tr><tr><td align="center" valign="middle" >Handedness (right/left)</td><td align="center" valign="middle" >41/2</td><td align="center" valign="middle" >32/1</td><td align="center" valign="middle" >41/2</td><td align="center" valign="middle" >0.134</td><td align="center" valign="middle" >0.935</td></tr><tr><td align="center" valign="middle" >Hypertension</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >1.792</td><td align="center" valign="middle" >0.421</td></tr><tr><td align="center" valign="middle" >Cardiac disease</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >0.208</td><td align="center" valign="middle" >0.901</td></tr><tr><td align="center" valign="middle" >Diabetes</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >2.109</td><td align="center" valign="middle" >0.348</td></tr><tr><td align="center" valign="middle" >Stroke</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >2.466</td><td align="center" valign="middle" >0.291</td></tr><tr><td align="center" valign="middle" >Smoke</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >1.691</td><td align="center" valign="middle" >0.429</td></tr><tr><td align="center" valign="middle" >Drink</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >3.527</td><td align="center" valign="middle" >0.171</td></tr><tr><td align="center" valign="middle" >BMI</td><td align="center" valign="middle" >25.57 &#177; 2.736</td><td align="center" valign="middle" >25.69 &#177; 2.666</td><td align="center" valign="middle" >25.02 &#177; 2.445</td><td align="center" valign="middle" >0.738</td><td align="center" valign="middle" >0.480</td></tr><tr><td align="center" valign="middle" >MMSE</td><td align="center" valign="middle" >25.16 &#177; 3.866</td><td align="center" valign="middle" >25.13 &#177; 3.180</td><td align="center" valign="middle" >26.14 &#177; 2.455</td><td align="center" valign="middle" >1.298</td><td align="center" valign="middle" >0.277</td></tr><tr><td align="center" valign="middle" >MoCA</td><td align="center" valign="middle" >21.37 &#177; 5.790</td><td align="center" valign="middle" >21.88 &#177; 4.218</td><td align="center" valign="middle" >22.74 &#177; 3.317</td><td align="center" valign="middle" >0.980</td><td align="center" valign="middle" >0.379</td></tr><tr><td align="center" valign="middle" >HMLD</td><td align="center" valign="middle" >5.60 &#177; 3.704</td><td align="center" valign="middle" >5.84 &#177; 3.409</td><td align="center" valign="middle" >6.77 &#177; 3.184</td><td align="center" valign="middle" >1.342</td><td align="center" valign="middle" >0.265</td></tr><tr><td align="center" valign="middle" >ADLs</td><td align="center" valign="middle" >27.23 &#177; 10.585</td><td align="center" valign="middle" >29.22 &#177; 10.162</td><td align="center" valign="middle" >27.98 &#177; 9.728</td><td align="center" valign="middle" >0.352</td><td align="center" valign="middle" >0.704</td></tr></tbody></table></table-wrap><p>BMI: body mass index; MMSE: mini-mental state examination; MoCA: Montreal cognitive assessment; ADLs: activities of daily living; HMLD: Hamilton rating scale for depression.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Neuropsychologic test scores at baseline and follow-up</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  ></th><th align="center" valign="middle" >Baseline</th><th align="center" valign="middle" >3 months</th><th align="center" valign="middle" >t</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >Control</td><td align="center" valign="middle" >MMSE</td><td align="center" valign="middle" >26.14 &#177; 2.455</td><td align="center" valign="middle" >26.02 &#177; 2.335</td><td align="center" valign="middle" >1.000</td><td align="center" valign="middle" >0.323</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >MoCA</td><td align="center" valign="middle" >22.74 &#177; 3.317</td><td align="center" valign="middle" >22.84 &#177; 3.177</td><td align="center" valign="middle" >−0.409</td><td align="center" valign="middle" >0.685</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >ADLs</td><td align="center" valign="middle" >27.98 &#177; 9.728</td><td align="center" valign="middle" >24.53 &#177; 3.686</td><td align="center" valign="middle" >2.375</td><td align="center" valign="middle" >0.022</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >HMLD</td><td align="center" valign="middle" >6.77 &#177; 3.184</td><td align="center" valign="middle" >5.07 &#177; 2.658</td><td align="center" valign="middle" >3.907</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >CAS</td><td align="center" valign="middle" >MMSE</td><td align="center" valign="middle" >25.16 &#177; 3.866</td><td align="center" valign="middle" >26.37 &#177; 3658</td><td align="center" valign="middle" >−5.061</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >MoCA</td><td align="center" valign="middle" >21.37 &#177; 5.790</td><td align="center" valign="middle" >23.23 &#177; 5.227</td><td align="center" valign="middle" >−4.699</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >ADLs</td><td align="center" valign="middle" >27.23 &#177; 10.585</td><td align="center" valign="middle" >23.37 &#177; 7.499</td><td align="center" valign="middle" >2.267</td><td align="center" valign="middle" >0.029</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >HMLD</td><td align="center" valign="middle" >5.60 &#177; 3.704</td><td align="center" valign="middle" >3.60 &#177; 3.685</td><td align="center" valign="middle" >3.631</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >EC-IC</td><td align="center" valign="middle" >MMSE</td><td align="center" valign="middle" >25.13 &#177; 3.180</td><td align="center" valign="middle" >26.59 &#177; 2.698</td><td align="center" valign="middle" >−5.239</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >MoCA</td><td align="center" valign="middle" >21.88 &#177; 4.218</td><td align="center" valign="middle" >24.13 &#177; 3.230</td><td align="center" valign="middle" >−4.962</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >ADLs</td><td align="center" valign="middle" >29.22 &#177; 10.162</td><td align="center" valign="middle" >24.09 &#177; 6.249</td><td align="center" valign="middle" >4.082</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >HMLD</td><td align="center" valign="middle" >5.84 &#177; 3.409</td><td align="center" valign="middle" >3.78 &#177; 2.779</td><td align="center" valign="middle" >3.524</td><td align="center" valign="middle" >0.001</td></tr></tbody></table></table-wrap><p>BMI: body mass index; MMSE: mini-mental state examination; MoCA: Montreal cognitive assessment; ADLs: activities of daily living; HMLD: Hamilton rating scale for depression.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Changes of neuropsychologic assessment scores at a 3-month follow up in the CAS, EC-IC by-pass and control groups</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >CAS (n = 43)</th><th align="center" valign="middle" >EC-IC (n = 32)</th><th align="center" valign="middle" >Control (n = 43)</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >MMSE</td><td align="center" valign="middle" >1.2093 &#177; 1.5669</td><td align="center" valign="middle" >1.4688 &#177; 1.5859</td><td align="center" valign="middle" >−0.1163 &#177; 0.7625</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >MoCA</td><td align="center" valign="middle" >1.8605 &#177; 2.5965</td><td align="center" valign="middle" >2.2500 &#177; 2.5653</td><td align="center" valign="middle" >0.0000 &#177; 1.3973</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >ADLs</td><td align="center" valign="middle" >−3.8605 &#177; 11.1667</td><td align="center" valign="middle" >−5.1250 &#177; 7.1018</td><td align="center" valign="middle" >−3.4419 &#177; 9.5026</td><td align="center" valign="middle" >0.011</td></tr><tr><td align="center" valign="middle" >HMLD</td><td align="center" valign="middle" >−2.0000 &#177; 3.2450</td><td align="center" valign="middle" >−2.0625 &#177; 3.3112</td><td align="center" valign="middle" >−1.6977 &#177; 2.8497</td><td align="center" valign="middle" >0.597</td></tr></tbody></table></table-wrap><p>BMI: body mass index; MMSE: mini-mental state examination; MoCA: Montreal cognitive assessment; ADLs: activities of daily living; HMLD: Hamilton rating scale for depression.</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of neuropsychologicassessment changes of both CAS and EC-IC by-pass patients with the controls</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >P CAS (n = 43)</th><th align="center" valign="middle" >P EC-IC (n = 32)</th></tr></thead><tr><td align="center" valign="middle" >MMSE</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >MoCA</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >ADLs</td><td align="center" valign="middle" >0.084</td><td align="center" valign="middle" >0.002</td></tr><tr><td align="center" valign="middle" >HMLD</td><td align="center" valign="middle" >0.378</td><td align="center" valign="middle" >0.394</td></tr></tbody></table></table-wrap><p>BMI: body mass index; MMSE: mini-mental state examination; MoCA: Montreal cognitive assessment; ADLs: activities of daily living; HMLD: Hamilton rating scale for depression.</p><p>EC-IC bypass surgery has been used to increase the cerebral blood flow and reduce the risk of future strokes in patients with ischemic cerebrovascular disease [<xref ref-type="bibr" rid="scirp.56947-ref25">25</xref>] [<xref ref-type="bibr" rid="scirp.56947-ref26">26</xref>] . With the cooperative study on EC-IC bypass in 1985 failing to show a benefit from the bypass procedure over medical management for anterior circulation occlusive disease [<xref ref-type="bibr" rid="scirp.56947-ref27">27</xref>] , the bypass procedure was almost abandoned by the mainstream neurosurgeons. Despite the disappointing findings of this study, a subpopulation of patients with ischemic vascular disease and poor hemodynamic reserve may benefit from EC-IC bypass. Given the above reason, a trail was carried out to re-evaluate the EC-IC bypass procedure. To our knowledge, there were few studies to explore the cognition changes after by-pass surgery. Our results showed that cognitive function improved in the patients with intracranial vascular stenosis and hemodynamic compromise three months after EC-IC by-pass. Besides, EC-IC bypass and CAS did not have the different outcome on cognitive performance. In our experience, the cognition improvement somehow was particularly apparent in the patients’ language. But we didn’t include verbal fluency tests in the patient’s neuropsychologic assessments.</p><p>We compared both ADLs and HMLD in all patients in a three-month follow-up. There was a significant improvement in instrumental daily living abilities and Hamilton depression scores in all the three groups, meanwhile EC-IC by-pass showed a superior effect on daily life abilities. Except for distinct advantage of EC-IC by-pass over patients’ living ability, all three treatments including CAS, EC-IC by-pass and medications were equally effective in improvement of patients’ living function and depression. Activities of daily living and neuropsychiatric amelioration may result from the cognitive improvement, the medication, or the spontaneous alleviation during the course of the cerebral ischemia.</p><p>There were few studies of the effects of both EC-IC by-pass and CAS on cognitive performance in patients with carotid and intracranial stenosis. We defined the patients who conformed to CAS/EC-IC by-pass criteria but declined any surgery as a control group, which greatly avoided the influence of some confounding factors on the results. But we only assessed neuropsychological function with the global cognitive tests, and some specific cognitive domains (i.e., attention and language, executive function) were not being evaluated with the pertinent neuropsychological examinations. Additionally, our study sample was small. Given the limited number of patients included in the analysis, our results should be considered as preliminary. A future study with larger patient populations and more specific cognitive assessments would be conducted to confirm these preliminary findings.</p></sec><sec id="s5"><title>5. Conclusion</title><p>The present study demonstrated that both CAS and EC-IC by-pass resulted in increased cognitive performance three months after procedures. Considering the limitation on sample size, further work is needed to confirm our current findings. With the widespread applying revascularization and increasing population of vascular cognitive impairment, it is important for randomized, controlled trials evaluating the benefits and risks of the procedures to include cognitive function assessments. Furthermore, understanding the effect of carotid and cerebral revascularization on cognition might help to reduce the incidence of vascular dementia.</p></sec><sec id="s6"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.56947-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Barnett, H.J., Taylor, D.W., Eliasziw, M., et al. (1998) Benefit of Carotid Endarterectomy in Patients with Symptomatic Moderate or Severe Stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. The New England Journal of Medicine, 339, 1415-1425. http://dx.doi.org/10.1056/NEJM199811123392002</mixed-citation></ref><ref id="scirp.56947-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Mathiesen, E.B., Waterloo, K., Joakimsen, O., et al. (2004) Reduced Neuropsychological Test Performance in Asymptomatic Carotid Stenosis: The Tromso Study. Neurology, 62, 695-701. http://dx.doi.org/10.1212/01.WNL.0000113759.80877.1F</mixed-citation></ref><ref id="scirp.56947-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Romero, J.R., Beiser, A., Seshadri, S., et al. (2009) Carotid Artery Atherosclerosis, MRI Indices of Brain Ischemia, Aging, and Cognitive Impairment: The Framingham Study. Stroke, 40, 1590-1596. http://dx.doi.org/10.1161/STROKEAHA.108.535245</mixed-citation></ref><ref id="scirp.56947-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">De la Torre, J.C. (2004) Is Alzheimer’s Disease a Neurodegenerative or a Vascular Disorder? Data, Dogma, and Dialectics. Lancet Neurology, 3, 184-190. http://dx.doi.org/10.1016/S1474-4422(04)00683-0</mixed-citation></ref><ref id="scirp.56947-ref5"><label>5</label><mixed-citation publication-type="book" xlink:type="simple">Norris, E.J. (2010) Anesthesia for Vascular Surgery. In: Miller, R.D., Ed., Miller’s Anesthesia, Churchill Livingstone Elsevier, Philadelphia. http://dx.doi.org/10.1016/B978-0-443-06959-8.00062-5</mixed-citation></ref><ref id="scirp.56947-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Derdeyn, C.P. (2007) Mechanisms of Ischemic Stroke Secondary to Large Artery Atherosclerotic Disease. Neuroimaging Clinics of North America, 17, 303-311. http://dx.doi.org/10.1016/j.nic.2007.03.001</mixed-citation></ref><ref id="scirp.56947-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Zlokovic, B.V. (2005) Neurovascular Mechanisms of Alzheimer’s Neurodegeneration. Trends in Neurosciences, 28, 202-208. http://dx.doi.org/10.1016/j.tins.2005.02.001</mixed-citation></ref><ref id="scirp.56947-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Nishio, K., Ihara, M., Yamasaki, N., et al. (2010) A Mouse Model Characterizing Features of Vascular Dementia with Hippocampal Atrophy. Stroke, 41, 1278-1284. http://dx.doi.org/10.1161/STROKEAHA.110.581686</mixed-citation></ref><ref id="scirp.56947-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Lin, M.S., Chiu, M.J., Wu, Y.W., et al. (2011) Neurocognitive Improvement after Carotid Artery Stenting in Patients with Chronic Internal Carotid Artery Occlusion and Cerebral Ischemia. Stroke, 42, 2850-2854. http://dx.doi.org/10.1161/STROKEAHA.111.613133</mixed-citation></ref><ref id="scirp.56947-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Lal, B.K., Younes, M., Cruz, G., et al. (2011) Cognitive Changes after Surgery vs Stenting for Carotid Artery Stenosis. Journal of Vascular Surgery, 54, 691-698. http://dx.doi.org/10.1016/j.jvs.2011.03.253</mixed-citation></ref><ref id="scirp.56947-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Grunwald, I.Q., Papanagiotou, P., Reith, W., Backens, M., Supprian, T., Politi, M., et al. (2010) Influence of Carotid Artery Stenting on Cognitive Function. Neuroradiology, 52, 61-66. http://dx.doi.org/10.1007/s00234-009-0618-4</mixed-citation></ref><ref id="scirp.56947-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Dong, Y.H., Teoh, H.L., Chan, B.P.L., Ning, C., Yeo, T.T., Sinha, A.K., et al. (2012) Changes in Cerebral Hemodynamic and Cognitive Parameters after External Carotid-Internal Carotid Bypass Surgery in Patients with Severe Steno-Occlusive Disease: A Pilot Study. Journal of the Neurological Sciences, 322, 112-116.http://dx.doi.org/10.1016/j.jns.2012.07.034</mixed-citation></ref><ref id="scirp.56947-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Bendszus, M. and Stoll, G. (2006) Silent Cerebral Ischaemia: Hidden Fingerprints of Invasive Medical Procedures. The Lancet Neurology, 5, 364-572. http://dx.doi.org/10.1016/S1474-4422(06)70412-4</mixed-citation></ref><ref id="scirp.56947-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Brott, T.G., Hobson II, R.W., Howard, G., Roubin, G.S., Clark, W.M., Brooks, W., et al. (2010) Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis. New England Journal of Medicine, 363, 11-23.http://dx.doi.org/10.1056/NEJMoa0912321</mixed-citation></ref><ref id="scirp.56947-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Hassoun, H.T., Malas, M.B. and Freischlag, J.A. (2010) Secondary Stroke Prevention in the Era of Carotid Stenting: Update on Recent Trials. Archives of Surgery, 145, 928-935. http://dx.doi.org/10.1001/archsurg.2010.204</mixed-citation></ref><ref id="scirp.56947-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Gaudet, J.G., Meyers, P.M. and McKinsey, J.F. (2009) Incidence of Moderate to Severe Cognitive Dysfunction in Patients Treated with Carotid Artery Stenting. Neurosurgery, 65, 325-330.http://dx.doi.org/10.1227/01.NEU.0000349920.69637.78</mixed-citation></ref><ref id="scirp.56947-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">De Rango, P., Caso, V., Leys, D., Paciaroni, M., Lenti, M. and Cao, P. (2008) The Role of Carotid Artery Stenting and Carotid Endarterectomy in Cognitive Performance: A Systematic Review. Stroke, 39, 3116-3127.http://dx.doi.org/10.1161/STROKEAHA.108.518357</mixed-citation></ref><ref id="scirp.56947-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Turk, A.S., Chaudry, I., Haughton, V.M., Hermann, B.P., Rowley, H.A., Pulfer, K., et al. (2008) Effect of Carotid Artery Stenting on Cognitive Function in Patients with Carotid Artery Stenosis: Preliminary Results. American Journal of Neuroradiology, 29, 265-268. http://dx.doi.org/10.3174/ajnr.A0828</mixed-citation></ref><ref id="scirp.56947-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Mendiz, O.A., Sposato, L.A., Fabbro, N., Lev, G.A., Calle, A., Valdivieso, L.R., et al. (2012) Improvement in Executive Function after Unilateral Carotid Artery Stenting for Severe Asymptomatic Stenosis. Journal of Neurosurgery, 116, 179-184. http://dx.doi.org/10.3171/2011.9.JNS11532</mixed-citation></ref><ref id="scirp.56947-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Grunwald, I.Q., Supprian, T., Politi, M., Struffert, T., Falkai, P., Krick, C., et al. (2006) Cognitive Changes after Carotid Artery Stenting. Neuroradiology, 48, 319-323. http://dx.doi.org/10.1007/s00234-006-0064-5</mixed-citation></ref><ref id="scirp.56947-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Xu, G.L., Liu, X.F., Meyer, J.S., Yin, Q. and Zhang, R. (2007) Cognitive Performance after Carotid Angioplasty and Stenting with Brain Protection Devices. Neurological Research, 29, 251-255.http://dx.doi.org/10.1179/016164107X159216</mixed-citation></ref><ref id="scirp.56947-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Kostopanagiotou, G., Markantonis, S.L., Polydorou, M., Pandazi, A. and Kottis, G. (2005) Recovery and Cognitive Function after Fentanyl or Remifentanil Administration for Carotid Endarterectomy. Journal of Clinical Anesthesia, 17, 16-20. http://dx.doi.org/10.1016/j.jclinane.2004.03.008</mixed-citation></ref><ref id="scirp.56947-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Kastrup, A., Groschel, K., Krapf, H., Brehm, B.R., Dichgans, J. and Schulz, J.B. (2003) Early Outcome of Carotid Angioplasty and Stenting with and without Cerebral Protection Devices: A Systematic Review of the Literature. Stroke, 34, 813-819. http://dx.doi.org/10.1161/01.STR.0000058160.53040.5F</mixed-citation></ref><ref id="scirp.56947-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Eskandari, M.K. (2005) Cerebral Embolic Protection. Seminars in Vascular Surgery, 18, 95-100.http://dx.doi.org/10.1053/j.semvascsurg.2005.04.006</mixed-citation></ref><ref id="scirp.56947-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Yoshimoto, Y. and Kwak, S. (1995) Superficial Temporal Artery—Middle Cerebral Artery Anastomosis for Acute Cerebral Ischemia: The Effect of Small Augmentation of Blood Flow. Acta Neurochirurgica, 137, 128-137.http://dx.doi.org/10.1007/BF02187184</mixed-citation></ref><ref id="scirp.56947-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Pikus, H.J. and Heros, R.C. (1999) Stroke: Indications for Emergent Surgical Intervention. Clinical Neurosurgery, 45, 113-127.</mixed-citation></ref><ref id="scirp.56947-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">EC-IC Bypass Study Group (1985) Failure of Extracranial-Intracranial Arterial Bypass to Reduce the Risk of Ischemic Stroke: Results of an International Randomized Trial. New England Journal of Medicine, 313, 1191-1200.http://dx.doi.org/10.1056/NEJM198511073131904</mixed-citation></ref></ref-list></back></article>